C012 | NOVEL ANALYSIS OF RESULTS FROM THE PIVOTAL EPCORE NHL-1 STUDY: OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA AND COMPLETE RESPONSE AT 2-YEARS WITH EPCORITAMAB MONOTHERAPY

Background: Depth and duration of CR correlate with long-term outcomes in LBCL. Epcor is a subcutaneous CD3xCD20 bispecific antibody approved for the treatment (tx) of pts with DLBCL or high-grade BCL after ≥2 lines of tx (LOT). In the 3-y follow-up (FU) from NHL-1 (NCT03625037), epcor led to durab...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	P.L. Zinzani, Y. H. Karimi, J.M. Vose, M. Roost Clausen, D. Cunningham, U. Farooq, T. Feldman, H. Ghesquieres, W. Jurczak, K.M. Linton, T. Phillips, W.S. Kim, P. Jafarinasabian, M. Geybels, D. Soong, B. D. Månsson, C. W. Eskelund, M. Atiya, M. Hutchings, C. Thieblemont, C.Y. Cheah
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Ferrata Storti Foundation 2025-09-01
Sarja:	Haematologica
Linkit:	https://haematologica.org/article/view/12876
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!